Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
about
Investigation of the Bioequivalence of Rosuvastatin 20 mg Tablets after a Single Oral Administration in Mediterranean Arabs Using a Validated LC-MS/MS MethodEffect of CYP3A4∗1G and CYP3A5∗3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention.Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study.Platelet function testing as a biomarker for efficacy of antiplatelet drugs.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy.Ticagrelor - toward more efficient platelet inhibition and beyond.Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers.Metabolism of ticagrelor in patients with acute coronary syndromes
P2860
Q37339515-407107C3-3362-4882-9744-FA99FFF22A26Q37730915-247DB6E1-E88E-47D8-A5EA-07107A6FD4F0Q38401281-B8A0AD49-2691-46D5-A0F8-200663F88DDDQ38660595-5366EBF3-B123-4A3F-B2C1-746DD378C1A1Q38818086-255BE109-7FCC-484E-941F-93AAAFDE34C8Q38842001-D8B2EE11-3419-4F6C-92BD-4263DC3F63EFQ38974884-11C9FC21-4673-46FD-BE2E-9DB161F14546Q40789462-FA477A68-34DF-4A01-9F8B-1B93CC32E8ACQ42375730-C7B288F0-1200-4255-8ED9-9A7C208E775BQ48344587-CE2F807F-2097-4BE6-9E5E-33631929C8C5Q49337303-4327F648-6885-4BF2-9C13-BAF3B1939846Q49908641-B99BF28D-1D3A-447A-8536-E729AD7B27C8Q51019317-5D1B3639-6A71-4D02-85A2-83B7D910D636Q58799733-B7706DE7-F433-4C01-B7F7-21336DFC77A6
P2860
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
@en
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
@nl
type
label
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
@en
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
@nl
prefLabel
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
@en
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
@nl
P2093
P2860
P50
P356
P1476
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes.
@en
P2093
Bryan J Barratt
Christoph Varenhorst
Deepak Voora
Emil Hagström
Hugo A Katus
Niclas Eriksson
PLATO Investigators
Renli Teng
Richard C Becker
Steen Husted
P2860
P304
P356
10.1093/EURHEARTJ/EHV116
P50
P577
2015-05-02T00:00:00Z